Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 746

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 1A
Chunk 746
---
 effective intellectual property rights for our technologies, approved product or current or future product candidates, we may not be able to compete effectively in our markets; and

    ●
    our future success depends in part upon our ability to retain our executive and scientific teams, and to attract, retain and motivate other qualified personnel.

Because of the numerous risks
and uncertainties associated with product development and commercialization, we are unable to accurately predict the timing or amount
of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies
in addition to those expected or if there are any delays in the initiation and completion of our clinical trials or the development of
any of our product candidates, our expenses could increase.

31

We will need to raise additional capital to
meet our business requirements in the future, and such capital raising may be costly or difficult to obtain, and could dilute current
stockholders’ ownership interests.

Our future capital requirements
will depend on many factors, including the success and costs of our commercialization activities, including product marketing, sales,
and distribution progress, the results of our clinical trials, the timing and outcome of regulatory review of our product candidates,
commercial manufacturing success, and the number and development requirements of product candidates that we pursue. Because of the numerous
risks and uncertainties associated with the development and commercialization of our approved product and product candidates, we are unable
to reasonably estimate the amounts of additional capital outlays and operating expenditures that our business will require. We will need
to raise additional funds through public or private debt or equity financings to meet various objectives including, but not limited to:

    ●
    expanding commercialization of our approved product;

    ●
    clinical trials for our product candidates;

    ●
    researching and developing new products;

    ●
    pursuing growth opportunities, including more rapid expansion;

    ●
    acquiring complementary businesses or technologies;

    ●
    making capital improvements to improve our infrastructure;

    ●
    hiring qualified management and key employees;

    ●
    responding to competitive pressures;

    ●
    complying with regulatory requirements; and

    ●
    maintaining compliance with applicable laws.

Any additional capital raised
through the sale of equity or equity-linked securities may dilute our current stockholders’ ownership in us and could also result
in a decrease in the market price of our common stock. The terms of those securities issued by us in future capital transactions may be
more favorable to new investors and may